Evaluating Quality of Life After Radiation Therapy for Liver Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the quality of life in patients with hepatocellular carcinoma who undergo stereotactic body radiation therapy (SBRT). Participants will receive standard treatment and follow-up care, with additional quality of life measurements taken at various time points using validated questionnaires. The study will involve imaging techniques and individualized treatment planning based on specific patient factors. The focus is on understanding how SBRT impacts patients' overall well-being over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically or radiologically proven hepatocellular carcinoma
* 1-3 lesions suitable for stereotactic radiation therapy
* indication for SBRT according to multidisciplinary board evaluation
* age \>= 18 years
* written informed consent for study participation
* mental and verbal ability to complete standardized questionaires according to assessment by investigator (physician)

Exclusion Criteria:

* age \< 18 years
* prior HCC specific systemic therapy
* concurrent oncological systemic treatment
* distant metastases
* inadequate ability tobe compliant with the protocol or to complete standardizes questionaires
* inability to receive contrast-enhanced planning CT
* missing ability to give informed consent
* legal custody

Where it's running

• Department of Radiation Oncology, University Hospital, LMU Munich
  Munich, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Falk Roeder, MD — Department of Radiation Oncology, University Hospital, LMU Munich
• Study coordinator: Falk Roeder, MD
• Email: Falk.Roeder@med.uni-muenchen.de
• Phone: +49 89 4400 73729

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Assessing the effects of ABBV-324 on liver and lung cancers

  This study is testing a new drug called ABBV-324 to see if it can help adults with advanced liver or lung cancer feel better when taken alone or with another medication.

  Recruiting at 21 sites Phase 1 AbbVie · Duarte, California and 21 other locations · NCT06858813

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Combining radiation therapy with hormone treatment for prostate cancer

  This study is testing if adding a special type of radiation therapy to standard treatment can help men with a specific kind of prostate cancer live better and longer.

  Recruiting Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Madrid and 1 other locations · NCT05209243

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.